BioCurex Files New RECAF Patent - New Methods For Tumor Imaging And Therapy Based On RECAF

Main Category: MRI / PET / Ultrasound
Also Included In: Radiology / Nuclear Medicine;  Medical Devices / Diagnostics;  Cancer / Oncology
Article Date: 30 Jul 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

BioCurex Inc. has announced that it has filed a new patent application to protect certain methods of purifying and detecting RECAF in bodily fluids. The patent application also includes what the company believes - based on available information - to be new methods for tumor imaging and therapy based on RECAF.

The patent application has been filed as a provisional patent application. This means that the patent application remains undisclosed for up to 18 months at the owner's discretion, thus providing one more year of protection, and, assuming the patent application is granted, therefore providing further RECAF technology protection for another 21 years.

This patent application contains critical methods necessary for manufacturing RECAF tests as well as for the generation of synthetic products to be used to target RECAF in-vivo (inside the body). These products can be manufactured at low cost, in highly pure form and without the need to use biological systems; thus eliminating the possibility of carrying infectious diseases to the recipients.

As a result of the protection provided by this new patent application, the company has forfeited its former patent application in Japan, where differences in patent law as compared to the USA and the EU, have resulted in unanticipated resistance to approval. BioCurex holds granted patents in the USA, the European Union, Russia, Australia, Norway and China at this time.

The new application will soon be extended through the Patent Cooperation Treaty to the most populated and developed countries with highest market potential, as we have done previously.

Dr. Moro, BioCurex's CEO stated: 'This new patent application is the result of several years of intense work and it reflects the value added to our company resulting from that investment in time and money. We - and our licensees - have been using technology contained in our issued patents for some time now, in our daily work. There are other improvements that will be the subject of new patent applications to be filed in the near future. This strategy is intended to stake the RECAF technology with a number of patent claims in a way that will prevent others from circumventing our patents as well as extending the protection period of our technology. '

The additional protection, offered by the claims related to blood tests in this new patent application, is extended to our current licensees. This will extend the term of our licensing agreements and therefore enhance our royalties. However, there are also other claims related to different fields and applications not encompassed in our current agreements and they can be freely licensed to new recognized licensees.

About BioCurex

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories and with Inverness Medical Innovations (for further information on these agreements click here.

The cancer marker RECAFTM has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.

The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are 'forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

Biocurex